What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2026-03-30 compared with 2025-03-31 · 425 added, 1458 removed, 6 unchanged (100% of the section changed)

You should carefully consider the following

material risk factors as well as all other information set forth or referred to in this report before purchasing shares of our common

Investing in our common stock involves a high degree of risk.

We may not be successful in preventing the material adverse effects

that any of the following risks and uncertainties may cause.

These potential risks and uncertainties may not be a complete list of the

risks and uncertainties facing us.

There may be additional risks and uncertainties that we are presently unaware of, or presently consider

immaterial, that may become material in the future and have a material adverse effect on us.

You could lose all or a significant portion

of your investment due to any of these risks and uncertainties.

Summary of Risk Factors

Our business is subject to numerous risks and

uncertainties that you should consider before investing in our company, as fully described below.

The principal factors and uncertainties

that make investing in our company risky include, among others:

Risks Related to the Potential Merger with

● The risk that the conditions to the closing of

the transaction are not satisfied, including the failure to obtain stockholder approval for the transaction.

● The timing, receipt and terms and conditions

of any required regulatory approvals of the Merger that could cause the parties to abandon the Merger.

● Our and YOOV’s ability to meet expectations

regarding the timing and completion of the Merger.

● Uncertainties as to the timing of the consummation

of the transaction and the ability of each of us and YOOV to consummate the transaction.

● Risks related to our continued listing on The

Nasdaq Capital Market until closing of the Merger.

● Risks that our stock price may decline significantly

if the Merger is not completed.

● The outcome of any legal proceedings that may

be instituted against us and others following the announcement of the Merger Agreement.

● Expectations regarding the strategies, prospects,

plans, expectations and objectives of management of us or YOOV for future operations of the combined company following the closing of

● The ability of the combined company to recognize

the benefits that may be derived from the Merger, including the commercial or market opportunity of the product candidates of YOOV and

the combined company.

● Risks related to our and YOOV’s ability

to correctly estimate their respective operating expenses and expenses associated with the transaction, uncertainties regarding the impact

any delay in the closing would have on the anticipated cash resources of the combined company upon closing and other events and unanticipated

spending and costs that could reduce the combined company’s cash resources.

● The occurrence of any event, change or other

circumstance or condition that could give rise to the termination of the Merger Agreement.

● The fact that under the terms of the Merger Agreement,

we are restrained from soliciting other acquisition proposals during the pendency of the Merger, except in certain circumstances.

● The effect of the announcement or pendency of

the Merger on our or YOOV’s business relationships, operating results and business generally, including disruption of our and YOOV’s

management’s attention from ongoing business operations due to the Merger and potential adverse reactions or changes to business

relationships resulting from the announcement or completion of the transaction.

● The risk that the Merger Agreement may be terminated

in circumstances that require us to pay a termination fee.

General Operating and Business Risks

● Our limited operating history

makes it difficult for us to evaluate our future business prospects and make decisions based on those estimates of our future performance.

● Our results of operations have

not resulted in profitability and we may not be able to achieve profitability going forward.

● There is substantial doubt

about our ability to continue as a going concern, which will affect our ability to obtain future financing and may require us to curtail

our operations.

● Our cash will only fund our

operations for a limited time and we will need to raise additional capital in order to support our development.

Joint ventures, joint ownership arrangements and other projects pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated benefits associated with such projects.

We must effectively manage the growth of our operations, or our company will suffer.

● Potential liability claims

may adversely affect our business.

● In accordance with our strategic

development policy, we may invest in companies for strategic reasons and may not realize a return on our investments.

● Obtaining and maintaining patent

protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental

patent agencies, and any patent protection we may obtain in the future could be reduced or eliminated for non-compliance with these requirements.

● It is difficult and costly

to protect our proprietary rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual

property rights adequately or secure rights to patents of others, the value of our intellectual property rights would diminish.

● If any of our trade secrets,

know-how or other proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be

significantly impaired and our business and competitive position would suffer.

Risk Factors Related to Commercialization

Some of our medical device

products in the future may face significant government regulation, and there is no guarantee that our medical devices will receive

regulatory approval.

Even if our medical

devices receive regulatory approval, we may still face future development and regulatory difficulties.

If we or our current or future collaborators, manufacturers, or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and substantial penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.

Any medical devices we develop may become subject to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business.

The healthcare industry is heavily regulated in the U.S.

at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties and negatively affect our financial condition.

Our ability to obtain reimbursement or funding from the federal government may be impacted by possible reductions in federal spending.

Risks Related to Our Securities

● Our officers, directors and

principal stockholders own a significant percentage of our capital stock and will be able to exert significant control over matters that

are subject to stockholder approval.

● If we are unable to maintain

listing of our securities on The Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our stockholders

to sell their securities.

● The price of our common stock

may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders.

● You may experience dilution

of your ownership interests because of the future issuance of additional shares of our common or preferred stock or other securities

that are convertible into or exercisable for our common or preferred stock.

Risks Related to the Potential Merger with

Failure to complete the Merger could negatively

impact the stock price and our future business and financial results.

The parties’ respective obligations to complete

the Merger are subject to the satisfaction or waiver of a number of conditions set forth in the Merger Agreement.

There can be no assurance

that the conditions to completion of the Merger will be satisfied or waived or that the Merger will be completed.

If the Merger is not

completed for any reason, our ongoing businesses may be materially and adversely affected and, without realizing any of the benefits of

having completed the Merger, We would be subject to a number of risks, including the following:

● we may experience negative reactions from the

financial markets, including negative impacts on the trading price of our common stock, which could affect our ability to secure sufficient

financing in the future on attractive terms (or at all) as a standalone company, and from their respective customers, vendors, regulators

and employees, and if we are unable to obtain additional capital, we may need to cease operations, dissolve or seek protection of bankruptcy

● we may be required to pay YOOV a termination

fee of $1,000,000 if we fail to consummate the Merger under specified circumstances;

● we will be required to pay certain expenses incurred

in connection with the Merger, whether or not the Merger is completed;

● the Merger Agreement places certain restrictions

on the operation of our business prior to the closing of the Merger, and such restrictions, the waiver of which is subject to the consent

of YOOV, may prevent us from making certain acquisitions, taking certain other specified actions or otherwise pursuing business opportunities

during the pendency of the Merger that we would have made, taken or pursued if these restrictions were not in place;

● matters relating to the Merger (including integration

planning) will require substantial commitments of time and resources by our management and the expenditure of significant funds in the

form of fees and expenses, which would otherwise have been devoted to day-to-day operations and other opportunities that may have been

beneficial to us as an independent company.

In addition, we could be subject to litigation

related to any failure to complete the Merger or related to any proceeding to specifically enforce our or YOOV’s obligations under

the Merger Agreement.

If any of these risks materialize, they may materially

and adversely affect our business, financial condition, financial results and stock prices.

We and YOOV will be subject to business uncertainties

and contractual restrictions while the Merger is pending.

Uncertainty about the effect of the Merger on

employees, vendors and customers may have an adverse effect on our or YOOV and consequently on the combined company after the closing

of the Merger.

These uncertainties may impair our and YOOV’s ability to retain and motivate key personnel and could cause customers

and others that deal with us and YOOV, as applicable, to defer or decline entering into contracts with us or YOOV, as applicable, or making

other decisions concerning us or YOOV, as applicable, or seek to change existing business relationships with us or YOOV, as applicable.

In addition, if key employees depart because of uncertainty about their future roles and the potential complexities of the Merger, our

and YOOV’s businesses could be harmed.

Furthermore, the Merger Agreement places certain restrictions on the operation of our and

YOOV’s businesses prior to the closing of the Merger, which may delay or prevent us and YOOV from undertaking certain actions or

business opportunities that may arise prior to the consummation of the Merger.

Third parties may terminate or alter existing

contracts or relationships with us or YOOV.

Each of us and YOOV has contracts with customers,

vendors and other business partners which may require us or YOOV, as applicable, to obtain consents from these other parties in connection

with the Merger.

If these consents cannot be obtained, the counterparties to these contracts and other third parties with which us and/or

YOOV currently have relationships may have the ability to terminate, reduce the scope of or otherwise materially adversely alter their

relationships with either party in anticipation of the Merger, or with the combined company following the Merger.

The pursuit of such

rights may result in us and YOOV suffering a loss of potential future revenue, incurring liabilities in connection with a breach of such

agreements or losing rights that are material to their businesses.

Any such disruptions could limit the combined company’s ability

to achieve the anticipated benefits of the Merger.

The adverse effect of such disruptions could also be exacerbated by a delay in the

completion of the Merger or the termination of the Merger.

The Merger is subject to a number of closing

conditions and, if these conditions are not satisfied, the Merger Agreement may be terminated in accordance with its terms and the Merger

may not be completed.

In addition, the parties have the right to terminate the Merger Agreement under other specified circumstances, in

which case the Merger would not be completed.

The Merger is subject to a number of closing conditions

and, if these conditions are not satisfied or waived (to the extent permitted by law), the Merger will not be completed.

These conditions include, among others:

absence of certain legal impediments, (ii) effectiveness of the registration statement on Form S-4 relating to the Merger, (iv) obtaining

approval from our stockholders to (i) approve the issuance of the shares of our common stock to be issued to YOOV shareholders in

connection with the Merger pursuant to the rules of Nasdaq and (ii) amend our certificate of incorporation to effect a reverse stock split

of our common stock to the extent we and YOOV mutually agree implementing such reverse stock split is necessary to meet Nasdaq’s

listing requirements, (v) the approval of the Merger Agreement and the Merger by YOOV shareholders and (vi) the approval of the Nasdaq

listing application and the listing of the our shares on The Nasdaq Capital Market following the Merger.

In addition, each party’s

obligation to complete the Merger is subject to the accuracy of the other parties’ representations and warranties in the Merger

Agreement, the other parties’ compliance, in all material respects, with their respective covenants and agreements in the Merger

The conditions to the closing of the Merger may

not be fulfilled and, accordingly, the Merger may not be completed.

In addition, if the Merger is not completed by March 7, 2026, any

party may choose not to proceed with the Merger.

Moreover, the parties can mutually decide to terminate the Merger Agreement at any time

prior to the consummation of the Merger, before or after receipt of the requisite approvals by our stockholders and the YOOV shareholders,

each party may elect to terminate the Merger Agreement in certain other circumstances, as set forth in the Merger Agreement.

If the Merger

Agreement is terminated, we may incur substantial fees and expenses in connection with termination of such Agreement and we will not realize

the anticipated benefits of the Merger.

In addition, if the Merger is not completed, we may not have sufficient capital to continue to

operate our business in the long term and may become insolvent and be required to seek the protection of the bankruptcy courts and, without

additional funding or a strategic transaction, we would likely be delisted from Nasdaq.

We or YOOV may waive one or more of the closing

conditions to the Merger without re-soliciting stockholder approval.

Each of us and YOOV has the right to waive certain

of the closing conditions to the Merger.

Any such waiver may not require re-solicitation of stockholders, in which case stockholders of

us and shareholders of YOOV will not have the chance to change their votes as a result of any such waiver and we and YOOV will have the

ability to complete the Merger without seeking further stockholder approval.

Any determination whether to waive any condition to the Merger,

whether stockholder approval would be re-solicited as a result of any such waiver or whether this proxy statement/prospectus would be

amended as a result of any waiver will be made us or YOOV, as applicable, at the time of such waiver based on the facts and circumstances

as they exist at that time, and any such waiver could have an adverse effect on the combined company.

Our stockholders will have a reduced ownership

and voting interest after the Merger and will exercise less influence over management.

Our stockholders, as a group have significantly

reduced ownership and voting power in the combined company compared to their current ownership and voting power in us.

In particular,

upon consummation of the Merger, our stockholders, as a group, will own less than 3% of the outstanding common stock of us.

our stockholders, as a group, will be able to exercise less collective influence over the management and policies of the combined company

than they currently exercise over the management and policies of us.

The Merger Agreement limits our ability to

pursue alternatives to the Merger.

The Merger Agreement contains provisions that

make it more difficult for us to enter into alternative transactions.

The Merger Agreement contains certain provisions that restrict our

ability to solicit or facilitate proposals from third parties with respect to transactions involving the financing or sale of us, or provide

non-public information to, or otherwise participate or engage in discussions or negotiations with, third parties or take certain other

actions that would reasonably be expected to lead to a third-party acquisition proposal.

Further, there are only limited exceptions to

our agreement that our board of directors will not change its recommendation in favor of the adoption of the Merger Agreement.

at any time prior to the receipt of the requisite stockholder approval by our stockholders and the approval of the Merger Agreement and

the Merger by YOOV shareholders, in response to an unsolicited superior proposal made by a third party, Our board of directors may make

an adverse recommendation change, and terminate the Merger Agreement to enter into an alternative acquisition agreement, if it concludes

in good faith, after consultation with outside financial advisors and outside legal counsel, that the failure to take such action would

be inconsistent with the fiduciary duties of our board of directors under the circumstances and under applicable law.

As described above, we may be required to pay

a termination fee of $1,000,000 to YOOV if the Merger is not consummated under specified circumstances as set forth in the Merger Agreement.

Upon obtaining the requisite approvals from our stockholders and YOOV shareholders, our right to terminate the Merger Agreement in response

to a Superior Proposal (as defined in the Merger Agreement) will cease.

While we believe these provisions are reasonable,

customary and not preclusive of other offers, the provisions might discourage a third party that has an interest in acquiring all or a

significant part of us from considering or proposing such an acquisition, even if such party were prepared to pay consideration with a

higher per-share value than the currently proposed merger consideration or if such party were prepared to enter into an agreement that

may be more favorable to us or our stockholders.

Our executive officers and directors may have

interests in the Merger that are different from, or in addition to, the rights of their respective stockholders.

Our executive officers negotiated the terms of

the Merger Agreement and the board of directors approved the Merger Agreement and the Merger and recommend that each stockholder vote

in favor of the proposals to be presented at the special meeting in connection with the Merger.

These executive officers and directors

may have interests in the Merger that are different from, or in addition to, our stockholders.

These interests include the potential continued

employment or retention as consultants of certain executive officers of us with the combined company following the Merger, the continued

service of certain of our directors as directors of the combined company following the Merger and the indemnification of our executive

officers and directors.

We, YOOV and, subsequently, the combined company

may have difficulty attracting, motivating and retaining executives and other key employees in light of the proposed Merger.

The combined company’s success after the

Merger will depend in part on each of our and YOOV’s ability to retain key executives and other employees.

Uncertainty about the

effect of the Merger on our and YOOV’s employees may have an adverse effect on each company separately and consequently, the combined

This uncertainty may impair the combined company’s ability to attract, retain and motivate key personnel.

Employee retention

may be particularly challenging during the pendency of the Merger, as our and YOOV’s employees may experience uncertainty about

their future roles in the combined business.

YOOV’s common stock

Furthermore, if any of our or YOOV’s key

employees depart or are at risk of departing, including because of issues relating to the uncertainty and difficulty of integration, financial

security or a desire not to become employees of the combined business, we or YOOV, as applicable, may have to incur significant costs

in retaining such individuals or in identifying, hiring and retaining replacements for departing employees and may lose significant expertise

and talent, and the combined company’s ability to realize the anticipated benefits of the Merger may be materially and adversely

No assurance can be given that the combined company will be able to attract or retain key employees to the same extent that

we or YOOV have been able to attract or retain employees in the past.

We will incur significant transaction and Merger-related

transition costs in connection with the Merger.

We expect that we will incur significant, non-recurring

costs in connection with consummating the Merger and integrating the operations of the two companies post-Closing.

We will incur significant

fees and expenses relating to financing arrangements and legal services (including any costs that would be incurred in defending against

any potential class action lawsuits and derivative lawsuits in connection with the Merger if any such proceedings are brought), accounting

and other fees and costs, associated with consummating the Merger.

Some of these costs are payable regardless of whether the Merger is

In addition, we may be required to pay a termination fee of $1,000,000 if the Merger Agreement is terminated under specified

circumstances described in the Merger Agreement.

Though we continue to assess the magnitude of these costs, additional unanticipated costs

may be incurred in the Merger and the integration of the businesses of us and YOOV.

We may be the target of securities class action

and stockholder lawsuits which could result in substantial costs and may delay or prevent the Merger from being completed.

Securities class action lawsuits and stockholder

lawsuits are often brought against public companies that have entered into merger agreements.

Even if the lawsuits are without merit,

defending against these claims can result in substantial costs and divert management time and resources.

An adverse judgment could result

in monetary damages, which could have a negative impact on our liquidity and financial condition.

Additionally, if a plaintiff is successful

in obtaining an injunction prohibiting completion of the Merger, then that injunction may delay or prevent the Merger from being completed,

which may adversely affect our or the combined company’s business, financial position and results of operations.

As of the date

of this report, no such lawsuits have been filed in connection with the Merger and the parties cannot predict whether any will be filed.

General Operating and Business Risks

Our limited revenue makes it difficult for

us to evaluate our future business prospects and make decisions based on those estimates of our future performance .

We have limited operating revenue.

Because of the uncertainties related

to our lack of significant revenue, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in revenues

If we make poor budgetary decisions as a result of unreliable historical data, we could be less profitable or incur losses,

which may result in a decline in our stock price.

Our results of operations have not resulted

in profitability and we may not be able to achieve profitability going forward.

We incurred net losses amounting to approximately $7.9 million and

$16.7 million for the years ended December 31, 2024 and 2023, respectively.

As of December 31, 2024, we had an accumulated deficit of

approximately $87.7 million.

If we incur additional significant losses, our stock price may decline, perhaps significantly.

Our management

is developing plans to achieve profitability.

Our business plan is speculative and unproven.

There is no assurance that we will be successful

in executing our business plan or that even if we successfully implement our business plan, that we will be able to curtail our losses

now or in the future.

Further, as we are a new enterprise, we expect that net losses will continue.

There is substantial doubt about our ability

to continue as a going concern, which will affect our ability to obtain future financing and may require us to curtail our operations.

Our financial statements as of December 31, 2024

were prepared under the assumption that we will continue as a going concern.

The independent registered public accounting firm that audited

our 2024 financial statements, in their report, included an explanatory paragraph referring to our recurring losses since inception and

expressing management’s assessment and conclusion that there is substantial doubt in our ability to continue as a going concern.

Our financial statements do not include any adjustments that might result from the outcome of this uncertainty.

An investment in our securities involves a

high degree of risk.

You should carefully consider the risks described below, together with all of the other information included in this

Annual Report, before making an investment decision.

Our business, financial condition, results of operations, and future prospects could

be materially and adversely affected by any of the following risks.

The trading price of our common stock could decline due to any of

these risks, and you may lose all or part of your investment.

The risks described below are not the only risks facing our company.

risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect

our business operations.

Risks Relating to Our Business and Operations

We have a limited operating history in our

current business segments, which makes it difficult to evaluate our business and future prospects.

We have a limited operating history in our current

We were initially pursuing a biotech platform and, through our acquisition of RPM in December 2025, have pivoted to primarily

operating as an AI company.

Because of this limited history, it is difficult to evaluate our proposed business and future prospects, including

our ability to plan for and model future growth, and there is no guarantee that our AI platform or Keto Air businesses will result in

profit or growth.

Investors should consider the risks, expenses, and difficulties frequently encountered by companies in the early stage

of development.

There can be no assurance that we will successfully address any of these risks.

We have a history of net losses and an

accumulated deficit, which raises substantial doubt about our ability to continue as a going concern.

Our results of operations have not resulted in

profitability.

We incurred net losses from continuing operations of approximately $17.5 million and $7.0 million for the years ended

December 31, 2025 and 2024, respectively.

As of December 31, 2025, we had an accumulated deficit of approximately $105.9 million.

is no assurance that we will be successful in executing our business plan or that we will be able to curtail our losses.

There is substantial

doubt about our ability to continue as a going concern.

Our independent registered public accounting firm has included an explanatory

paragraph in its audit report expressing substantial doubt about our ability to continue as a going concern.

Our ability to continue

as a going concern depends on our ability to obtain additional equity or debt financing, attain further operating efficiencies, reduce

expenditures, and, ultimately, to generate revenue.

We cannot assure you, however, that we will be able to achieve any of the foregoing.

See Note 2 to our Consolidated Financial Statements for further details.

Our cash will only fund our operations for

a limited time and we will need to raise additional capital in order to support our development.

We are currently operating at a loss and expect our operating costs

will increase significantly as we continue to grow our operations.

The independent registered public accounting firm that audited our

2024 financial statements, in their report, included an explanatory paragraph referring to our recurring losses since inception and expressing

management’s assessment and conclusion that there is substantial doubt in our ability to continue as a going concern.

31, 2024, we had cash of approximately $2.9 million.

We will need to raise additional capital or generate substantial revenue in order

to support our development and commercialization efforts.

If our available cash balances are insufficient

to satisfy our liquidity requirements, including due to risks described herein, we may seek to raise additional capital through equity

offerings, debt financings, collaborations or licensing arrangements.

We will need to raise additional capital, and we may also consider

raising additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities,

or for other reasons, including to:

● fund development and expansion

of our operations;

● acquire, license or invest

in technologies and additional laboratories;

● acquire or invest in complementary

businesses or assets;

● finance capital expenditures

and general and administrative expenses.

Our present and future funding requirements will

depend on many factors, including:

● our revenue growth rate and

ability to generate cash flows from operating activities;

● our sales and marketing and

research and development activities;

● changes in regulatory oversight

applicable to our products and services.

Other than our debt facility with our

chairman, we have no arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be

able to raise sufficient additional capital on acceptable terms, or at all, and if we are not successful in raising additional

capital, we may not be able to continue as a going concern.

We may seek additional capital through a combination of private and

public equity offerings, debt financings and strategic collaborations.

Debt financing, if obtained, may involve agreements that

include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, that could

increase our expenses and require that our assets secure such debt.

Equity financing, if obtained, could result in dilution to our

then existing stockholders and/or require such stockholders to waive certain rights and preferences.

If such financing is not

available on satisfactory terms, or is not available at all, we may be required to delay, scale back or eliminate the development of

business opportunities and our operations and financial condition may be materially adversely affected.

We can provide no assurances

that any additional sources of financing will be available to us on favorable terms, if at all.

Future capital raises may dilute our

existing stockholders’ ownership and/or have other adverse effects on our operations.

If we raise additional capital by issuing equity

securities, our existing stockholders’ percentage ownership will be reduced and these stockholders may experience substantial dilution.

If we raise additional funds by issuing debt securities,

these debt securities would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant

restrictions on our operations, including liens on our assets.

If we raise additional funds through collaborations and licensing arrangements,

we may be required to relinquish some rights to our technologies or products, or to grant licenses on terms that are not favorable to

We have significant outstanding debt obligations

and servicing these debt obligations will require a significant amount of capital, and our business may not be able to pay our substantial

As of December 31, 2024, we had approximately $8.4 million of outstanding

indebtedness.

In order to service this indebtedness and any additional indebtedness we may incur in the future, we will need to generate

cash from our operating activities.

Our ability to generate cash is subject, in part, to our ability to successfully execute our business

strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control.

If we are unable to generate

sufficient cash to repay our debt obligations when they become due and payable, either when they mature, or in the event of a default,

we may not be able to obtain additional debt or equity financing on favorable terms, if at all, which may negatively impact our business

operations and financial condition.

If we breach any of the undertakings or default

on any of our obligations under our agreements with our lenders, our outstanding indebtedness could become immediately due and payable,

which would harm our business, financial condition and results of operations and could require us to reduce or cease operations.

indebtedness were to be accelerated, there can be no assurance that our assets would be sufficient to repay in full that indebtedness.

Our business and operations may be further

impacted by epidemics, outbreaks and other public health events.

Epidemics, outbreaks or other public health events

that are outside of our control could significantly disrupt our operations and adversely affect our financial condition.

The global or

national outbreak of an illness or other communicable disease, or any other public health crisis, such as COVID-19, may cause disruptions

to our business and operations, which may include (i) shortages of employees, (ii) unavailability of contractors or subcontractors, (iii)

interruption of supplies from third parties upon which we rely, (iv) recommendations of, or restrictions imposed by government and health

authorities, including quarantines, to address an outbreak and (v) restrictions that we and our contractors, subcontractors and our customers

impose, including facility shutdowns, to ensure the safety of employees.

We depend upon key personnel and need additional

expenditures, and ultimately generate revenue.

We have not generated sustainable revenue since

inception, and we may not be able to generate sufficient revenue to achieve or maintain profitability.

We have not yet developed a meaningful customer

base and have not generated sustainable revenue since inception.

We are subject to the substantial risk of failure facing businesses seeking

to develop and commercialize new products and technologies, and maintaining and improving our platform will require significant capital.

Our Keto Air product has generated minimal revenue to date, and we anticipate that it will take approximately one year from the date of

this Annual Report for us to begin generating meaningful revenue from our RPM platform.

There can be no assurance that we will generate

revenue at the levels we anticipate, or at all, and our failure to do so could have a material adverse effect on our business, financial

condition, and results of operations.

We may not be successful in commercializing

our AI platform or our Keto Air product, either of which would materially harm our business.

We may not be successful in our AI vodcasting

and podcasting platform businesses or our sales of Keto Air.

Market acceptance of AI-driven offerings is uncertain, and we will rely on

other companies, developers, and partners to build our product offerings.

Additionally, evolving laws and regulations in areas such as

privacy, intellectual property, safety, competition, content regulation, and consumer protection may delay or impede the development of

our products and services.

Our Keto Air product is currently operating as an early-stage commercial activity, and we are continuing to

evaluate the future strategic direction of the Keto Air product line as we assess its commercial performance.

There can be no assurance

that either of our current business segments will achieve market acceptance or commercial viability.

Our RPM platform is in an early stage of

development and is based on new and evolving AI technologies, which are subject to significant uncertainty.

Our Catch-Up Vodcast and Podcast Platform is

currently under development and is based on new and evolving AI systems and technologies.

This exposes us to risks including failure

to gain market acceptance, inability to secure sufficient intellectual property rights, proprietary rights of third parties limiting

our marketing efforts, failure to obtain sufficient user exposure, superior competing products, and the unpredictability of AI

Our platform is currently in beta testing with a limited number of users, and Phase 2 of the platform — which will

expand our addressable market beyond podcasters — is currently in development and expected to launch in Q3 of 2026.

There can be no assurance that Phase 2 will be completed on schedule or that it will achieve the

commercial results we anticipate.

We face intense competition in both of our

business segments, and many of our competitors have substantially greater resources than we do.

We face intense competition from numerous technology

companies seeking to enter the generative AI-powered vodcasting and podcasting businesses.

Many of our current and potential competitors

have significantly larger market presence, greater name recognition, access to more potential customers, and substantially greater financial,

technical, sales, marketing, management, support, and other resources than we do.

In our consumer health technology segment, we compete

with manufacturers and distributors of urine-based ketone test strips and other breath-based ketone monitoring devices, many of which

have established retail distribution networks and marketing infrastructure that we currently lack.

Our failure to compete effectively

in either segment could have a material adverse effect on our business, financial condition, and results of operations.

Our business is subject to rapid technological

change, and if we fail to adapt, our business may be negatively impacted.

Our industry is subject to rapid technological

change, and if we do not adapt to and appropriately allocate resources among emerging technologies and business models, our business may

be negatively impacted.

Competitors may adapt to emerging technologies or business models more quickly or effectively than we do.

generative AI industry in particular is evolving at an exceptionally rapid pace, and technologies, platforms, and distribution channels

that are relevant to our business today may be superseded or disrupted in ways that we cannot currently anticipate.

We may encounter difficulties associated

with early-stage companies that could adversely affect our operations.

We may encounter numerous difficulties frequently

encountered by early-stage companies, including implementing our growth strategy, countering competitors, pursuing new users, maintaining

adequate expense control, attracting and retaining qualified personnel, reacting to user preferences, successfully launching products,

and maintaining regulatory compliance.

Failure to address any of these factors could have a material adverse effect on our business, financial

condition, results of operations, and future prospects.

Our success depends on the continued services

of our key personnel, the loss of whom could materially harm our business.

Our success depends on the continuing

services of Wenzhao Lu, our Chairman of the Board, and David Jin, Meng Li and Luisa Ingargiola, our executive officers.

Ingargiola could have a material and adverse effect on our business operations.

Additionally, the

success of our operations will largely depend upon our ability to successfully attract and maintain competent and qualified key

management personnel.

As with any company with limited resources, there can be no guaranty that we will be able to attract such

individuals or that the presence of such individuals will necessarily translate into profitability for us.

Our inability to attract

and retain key personnel may materially and adversely affect our business operations.

The supply of qualified technical,

professional, managerial and other personnel, including lab medical directors and lab operations managers, is currently constrained;

competition for qualified employees, even across different industries, is intense, including as individuals leave the job market.

may lose, or fail to attract and retain, key management personnel, or qualified skilled technical, professional or other employees.

The same is true for patient-facing staff with specialized training required to perform activities related to specimen collection.

In the future, if competition for the services of these professionals increases, we may not be able to continue to attract and

retain individuals in its markets.

Changes in key management, or the ability to attract and retain qualified personnel, as a result

of increased competition for talent, wage growth, or other market factors, could lead to strategic and operational challenges and

uncertainties, distractions of management from other key initiatives, and inefficiencies and increased costs, any of which could

adversely affect our business, financial condition, results of operations, and cash flows.

Joint ventures, joint ownership arrangements

and other projects pose unique challenges and we may not be able to fully implement or realize synergies, expected returns or other anticipated

benefits associated with such projects.

We are, and may be in the future, involved in

strategic joint ventures and other joint ownership arrangements.

We may not always be in complete alignment with our joint venture or

joint owner counterparties;

we may have differing strategic or commercial objectives and may be outvoted by our joint venture partners

or we may disagree on governance matters with respect to the joint venture entity or the jointly owned assets.

As a result, when we enter

into joint ventures or joint ownership arrangements, we may be subject to a number of risks.

In some joint ventures and joint ownership

arrangements we may not be responsible for the operation of projects and will rely on our joint venture or joint owner counterparties

for such services.

Joint ventures and joint ownership arrangements may also require us to expend additional internal resources that could

otherwise be directed to other projects.

If we are unable to successfully execute and manage our existing and any proposed joint venture

and joint owner arrangements, it could adversely impact our financial and operating results.

We may be undertaking, or participating with various

counterparties in, a number of projects that involve forming joint ventures and acquiring laboratories that are accretive to our commercial

Many of these projects could involve numerous regulatory, environmental, commercial, economic, political and legal uncertainties

that are beyond our control, including the following:

We may be unable to realize our forecasted commercial, operational or administrative synergies in connection with our joint venture and joint ownership arrangements;

● Joint ventures and other joint

ownership arrangements may demand substantial internal resources and may divert resources and attention from other areas of our business.

As a result of these uncertainties, the anticipated

benefits associated with our joint ventures and joint ownership arrangements may not be achieved or could be delayed.

In turn, this could

negatively impact our cash flow and our ability to make or increase cash distributions to our partners.

We must effectively manage the growth of our

operations, or our company will suffer.

To manage our growth, we believe we must continue

to implement and improve our services and products.

We may not have adequately evaluated the costs and risks associated with our planned

expansion, and our systems, procedures, and controls may not be adequate to support our operations.

In addition, our management may not

be able to achieve the rapid execution necessary to successfully offer our products and services and implement our business plan on a

profitable basis.

The success of our future operating activities will also depend upon our ability to expand our support system to meet

the demands of our growing business.

Any failure by our management to effectively anticipate, implement, and manage changes required to

sustain our growth would have a material adverse effect on our business, financial condition, and results of operations.

Our revenue and results of operations may suffer

if we are unable to attract new tenants.

We presently derive our revenue from rental revenue

from our income-producing real estate property in New Jersey.

Our growth therefore depends on our ability to attract new tenants.

depends on our ability to understand and anticipate market and pricing trends and our tenants’ needs.

Our failure to attract new

tenants could materially and adversely affect our operating results.

Potential liability claims may adversely affect

our business.

Our services, which may include recommendations

and advice to organizations regarding complex business and operational processes and regulatory and compliance issues may give rise to

liability claims by our clients or by third parties who bring claims against our clients.

Healthcare organizations often are the subject

of regulatory scrutiny and litigation, and we also may become the subject of such litigation based on our advice and services.

litigation, whether or not resulting in a judgment against us, may adversely affect our reputation and could have a material adverse effect

on our financial condition and results of operations.

We may not have adequate insurance coverage for claims against us.

In accordance with our strategic development

policy, we may invest in companies for strategic reasons and may not realize a return on our investments.

From time to time, we may make investments in companies.

These investments

may be for strategic objectives to support our key business initiatives but may also be standalone investments or acquisitions.

Such investments

or acquisitions could include equity or debt instruments in private companies, many of which may not be marketable at the time of our

initial investment.

These companies may range from early-stage companies that are often still defining their strategic direction to more

mature companies with established revenue streams and business models.

The success of these companies may depend on product development,

market acceptance, operational efficiency, and other key business factors.

The companies in which we invest may fail because they may

not be able to secure additional funding, obtain favorable investment terms for future financings, or take advantage of liquidity events

such as public offerings, mergers, and private sales.

If any of these private companies fails, we could lose all or part of our investment

in that company.

If we determine that impairment indicators exist and that there are other-than-temporary declines in the fair value of

the investments, we may be required to write down the investments to their fair value and recognize the related write-down as an investment

For the year ended December 31, 2024, we had an impairment of goodwill acquired from Lab Services MSO acquisition of approximately

$0.3 million.

In the future, we could have additional impairment charges related to investments that we may make.

Our strategic transactions involve risks, and

we may not realize the expected benefits because of numerous uncertainties and risks.

We regularly consider and may enter into strategic

transactions, including mergers, acquisitions, joint ventures, investments and other growth, market and geographic expansion strategies,

with the expectation that these transactions will result in increases in sales, cost savings, synergies, and other various benefits.

ability to deliver the expected benefits from any strategic transaction is subject to numerous uncertainties and risks, including our

ability to integrate personnel, labor models, financial, IT and other systems successfully;

disruption of our ongoing business and distraction

of management;

hiring additional management and other critical personnel;

and increasing the scope, geographic diversity, and complexity

of our operations.

Effective internal controls are necessary to provide reliable and accurate financial reports, and the integration of

businesses may create complexity in our financial systems and internal controls and make them more difficult to manage.

Integration of

businesses into our internal control system could cause us to fail to meet our financial reporting obligations.

Additionally, we may recognize

material impairments in the future, including in connection with assets we have acquired or divested in a strategic transaction or charges

to earnings associated with any strategic transaction, which may materially reduce our earnings.

Our shareholders may react unfavorably

to our strategic transactions and strategic transactions may also be subject to regulatory uncertainty due to the changing enforcement

We may not realize the anticipated benefits from such transactions, we may be exposed to additional liabilities of any acquired

business or joint venture, and we may be exposed to litigation in connection with the strategic transaction.

Further, we may finance these

strategic transactions by incurring additional debt, which could increase leverage or impact our ability to access capital in the future.

We face intense competition which could cause us to lose market

In the healthcare markets in which we operate,

we will compete with large healthcare providers who have more significant financial resources, established market positions, long-standing

relationships, and who have more significant name recognition, technical, marketing, sales, distribution, financial and other resources

The resources available to our competitors to develop new services and products and introduce them into the marketplace exceed

the resources currently available to us.

This intense competitive environment may require us to make changes in our services, products,

pricing, licensing, distribution, or marketing to develop a market position.

If we fail to comply with our obligations in

the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business

relationships with our licensors, we could lose intellectual property rights that are important to our business.

We are party to a research agreement with the

Massachusetts Institute of Technology (“MIT”) for development of chimeric antigen receptor (CAR) technology.

Although we have

halted all research and development, MIT has granted us options to non-exclusively or exclusively license MIT inventions arising under

this research agreement and we continue to maintain our joint patent applications.

Moreover, Disputes may arise regarding intellectual

property subject to a licensing agreement, including:

● the scope of rights granted

under the license agreement and other interpretation-related issues;

● the extent to which our product

candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

● the sublicensing of patent

and other rights under our collaborative development relationships;

● our diligence obligations under

the license agreement and what activities satisfy those diligence obligations;

● the inventorship and ownership

of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners;

● the priority of invention of

patented technology.

In addition, the agreements under which we currently

license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible

to multiple interpretations.

The resolution of any contract interpretation disagreement that may arise could narrow what we believe to

be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other

obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results

of operations, and prospects.

Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to

maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize

the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations,

and prospects.

services of Wenzhao Lu, our Chairman, Meng Li, Luisa Ingargiola, our Chief Financial Officer, our other executive officers, and

Michael Mathews, the Chief Executive Officer of RPM.

The loss of any of these individuals could have a material and adverse effect

on our business operations.

The supply of qualified technical, professional, managerial, and other personnel is currently

constrained, and competition for qualified employees is intense.

In particular, our former Chief Executive Officer, David Jin, was

instrumental in sourcing our Keto Air distribution rights through his personal industry relationships, and the loss of his services

could adversely affect the continuation and development of that segment.

Our strategy of continuing to evaluate

additional possible acquisitions to supplement our operations involves significant risks, and we may not be able to identify, complete,

or successfully integrate any such acquisitions.

We are actively evaluating complementary possible artificial intelligence

acquisitions that we believe could generate near-term revenue to supplement our current operations.

Strategic transactions, including

mergers, acquisitions, joint ventures, and investments, involve risks including the ability to integrate personnel, labor models, financial,

information technology, and other systems successfully;

disruption of ongoing business;

distraction of management;

and the possibility

of material impairments of goodwill or other assets.

We may not realize the anticipated benefits from such transactions and may be exposed

to additional liabilities of any acquired business.

We have previously pursued and terminated multiple acquisition transactions, including

our proposed merger with YOOV Group Holding Limited, and there can be no assurance that future acquisition efforts will result in completed

transactions or, if completed, that such transactions will deliver the anticipated strategic or financial benefits.

We depend on third parties for supplies

and services critical to our Keto Air business, and any disruption could adversely affect our operations.

We depend on third parties to provide supplies

and services critical to our Keto Air business and are heavily reliant on third-party ground and air travel for transport of supplies.

Disruptions to supply and services could have a material adverse effect on our Keto Air business.

We source the Keto Air device from a

single Hong Kong-based technology group pursuant to an exclusive distribution agreement, and any disruption to that supply relationship

— whether due to manufacturing issues, geopolitical developments, shipping disruptions, or other factors — could impair our

ability to fulfill customer orders and sustain revenue from this segment.

The termination of our proposed merger with

YOOV Group Holding Limited may continue to adversely affect our business, financial condition, and stock price.

The termination of the proposed merger with YOOV

Group Holding Limited may adversely affect our stock price, business, financial condition, and ability to raise capital;

result in unrecoverable

harm our reputation and relationships with investors, business partners, customers, vendors, and employees;

create strategic uncertainty;

and expose us to potential litigation or regulatory proceedings.

The three-year non-disparagement covenant in the Mutual Termination and

Release Agreement may also limit certain communications relating to the proposed merger and its termination.

Risks Relating to Artificial Intelligence and

The use of AI in our platform may give rise

to legal liability, reputational harm, and regulatory scrutiny.

Our use of AI in our vodcasting and podcasting

platform may give rise to risks related to harmful content, inaccuracies, discrimination, intellectual property infringement or misappropriation,

defamation, data privacy, and cybersecurity.

We intend to deploy open-source third-party AI systems that are relatively new to the commercial

market and may at times generate inaccurate or low-quality content, which could lead to reputational harm and legal liability.

consequences of AI tools may negatively affect human rights, privacy, employment, or other social concerns, resulting in claims, lawsuits,

brand or reputational harm, and increased regulatory scrutiny.

Our RPM platform's AI avatar feature, which

replicates individual voices and likenesses, exposes us to significant legal risks under right of publicity, biometric privacy, and related

The RPM platform generates AI-produced video content

featuring avatars that replicate the voice and likeness of content creators.

This functionality implicates state right of publicity laws

across the United States, which protect individuals against the unauthorized commercial use of their name, image, voice, and likeness.

Laws governing AI-generated synthetic media depicting real individuals vary significantly across states and are rapidly evolving, with

particularly robust statutory frameworks in California, New York, and Texas, among others.

Several states have recently enacted or are

actively considering legislation specifically addressing AI-generated synthetic media and voice cloning.

Additionally, the collection and processing of

voice and likeness data through our platform's avatar generation feature may implicate obligations under state biometric data privacy

laws, including the Illinois Biometric Information Privacy Act ("BIPA") and similar statutes in other states, which impose specific

consent, notice, retention, and data security requirements on the collection and use of biometric identifiers, including voiceprints.

Failure to comply with applicable right of publicity or biometric privacy laws could result in significant legal liability, regulatory

enforcement actions, and reputational harm.

There can be no assurance that the consent and authorization process we have implemented for

our platform's beta users will be sufficient to satisfy all applicable legal requirements as such laws continue to develop.

The content generated by our platform may

infringe the intellectual property rights of third parties, which could expose us to significant liability.

Our platform's content sourcing feature automatically

scrapes and curates video content from the internet for inclusion in AI-generated videos.

This process may result in the reproduction

or republication of content that is protected by copyright or other intellectual property rights of third parties.

While we intend to

implement appropriate content identification and licensing measures, there can be no assurance that all content sourced by our platform

will be free of third-party intellectual property claims.

If third parties claim that we infringe their intellectual property, it may

result in costly litigation.

We may not be able to adequately protect our proprietary technology, and competitors may be able to offer

similar products and services.

Any such claims, regardless of their merit, could result in significant legal costs, distract management,

and adversely affect our business.

We may not be able to protect our intellectual

property rights, which could impair our competitive position.

We may face uncertainty and difficulty in obtaining

and enforcing our patents and other proprietary rights.

There can be no assurance that any patent applications

we file or license will be approved, or that challenges will not be instituted against the validity or enforceability of any patent licensed-in

or owned by us.

Our pending and future patent applications may not result in patents being issued that protect our product candidates,

in whole or in part, or which effectively prevent others from commercializing competitive product candidates.

Even if our patent applications

issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing

with us or otherwise provide us with any competitive advantage.

Our competitors may be able to circumvent our patents by developing similar

or alternative product candidates in a non-infringing manner.

The cost of litigation to uphold the validity and prevent infringement of

a patent is substantial.

Furthermore, there can be no assurance that others will not independently develop substantially equivalent technologies

not covered by patents to which we have rights or obtain access to our know-how.

In addition, the laws of certain countries may not adequately

protect our intellectual property.

Our competitors may possess or obtain patents on products or processes that are necessary or useful

to the development, use, or manufacture of our product candidates.

There can also be no assurance that our proposed technology will not

infringe upon patents or proprietary rights owned by others, with the result that others may bring infringement claims against us and

require us to license such proprietary rights, which may not be available on commercially reasonable terms, if at all.

Any such litigation,

if instituted, could have a material adverse effect, potentially including monetary penalties, diversion of management resources, and

injunction against continued manufacture, use, or sale of certain products or processes.

We rely upon non-patented proprietary know-how.

There can be no assurance that we can adequately protect our rights in such non-patented proprietary know-how, or that others will not

independently develop substantially equivalent proprietary information or techniques or gain access to our proprietary know-how.

the foregoing events could have a material adverse effect on us.

In addition, if any of our trade secrets, know-how or other proprietary

information were to be disclosed, or misappropriated, the value of our trade secrets, know-how and other proprietary rights would be significantly

impaired and our business and competitive position would suffer.

In September 2011, the Leahy-Smith America Invents

Act, or the Leahy-Smith Act, was signed into law.

The Leahy-Smith Act includes a number of significant changes to U.S.

include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation.

In particular, under

the Leahy-Smith Act, the United States transitioned in March 2013 to a “first to file” system in which the first inventor

to file a patent application will be entitled to the patent.

Third parties are allowed to submit prior art before the issuance of a patent

Patent and Trademark Office, or USPTO, and may become involved in opposition, derivation, post-grant and inter partes review,

or interference proceedings challenging our patent rights.

An adverse determination in any such submission, proceeding or litigation could

reduce the scope of, or invalidate, our patent rights, which could adversely affect our competitive position.

The USPTO has developed new and untested

regulations and procedures to govern the full implementation of the Leahy-Smith Act, and many of the substantive changes to patent

law associated with the Leahy-Smith Act, and in particular, the “first-to-file” provisions, only became effective in

The Leahy-Smith Act has also introduced procedures that may make it easier for third parties to challenge issued

patents, as well as to intervene in the prosecution of patent applications.

Finally, the Leahy-Smith Act contains new statutory

provisions that still require the USPTO to issue new regulations for their implementation, and it may take the courts years to

interpret the provisions of the new statute.

Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the

operation of our business.

The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the

prosecution of our patent applications and the enforcement or defense of our issued patents.

We may not be able to protect our intellectual

property rights throughout the world.

Filing, prosecuting and defending patents on our

product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some

countries outside the United States may be less extensive than those in the United States.

In addition, the laws of some foreign countries

do not protect intellectual property rights to the same extent as federal and state laws in the United States.

Consequently, we may not

be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing

products made using our inventions in and into the United States or other jurisdictions.

Competitors may use our technologies in jurisdictions

where we do not obtain patent protection to develop their own products and may also export infringing products to territories where we

have patent protection, but enforcement is not as strong as that in the United States.

These products may compete with our products and

our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems

in protecting and defending intellectual property rights in foreign jurisdictions.

The legal systems of certain countries, particularly

certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly

those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of

competing products in violation of our proprietary rights generally.

Proceedings to enforce our patent rights in foreign jurisdictions,

whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,

could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could

provoke third parties to assert claims against us.

We may not prevail in any lawsuits that we initiate and the damages or other remedies

awarded, if any, may not be commercially meaningful.

Accordingly, our efforts to enforce our intellectual property rights around the world

may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Patent terms may be inadequate to protect our

competitive position on our product candidates for an adequate amount of time.

Patents have a limited lifespan.

In the United

States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S.

non-provisional

Various extensions may be available, but the life of a patent, and the protection it affords, is limited.

Even if patents

covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products,

including generics or biosimilars.

Given the amount of time required for the development, testing and regulatory review of new product

candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.

As a result, any

patents we may obtain may not provide us with sufficient rights to exclude others from commercializing products similar or identical to

Obtaining and maintaining patent protection

depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent

agencies, and any patent protection we may obtain in the future could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance fees, renewal fees, annuity

fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental

patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications.

The USPTO and various

governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions

during the patent application process.

There are situations in which non-compliance can result in abandonment or lapse of the patent

or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.

In such an event, our competitors

might be able to enter the market and this circumstance would have a material adverse effect on our business.

It is difficult and costly to protect our proprietary

rights, and we may not be able to ensure their protection.

If we fail to protect or enforce our intellectual property rights adequately

or secure rights to patents of others, the value of our intellectual property rights would diminish.

Our commercial viability will depend in part on

obtaining and maintaining patent protection and trade secret protection of our product candidates, and the methods used to manufacture

them, as well as successfully defending these patents against third-party challenges.

Our ability to stop third parties from making, using,

selling, offering to sell, or importing our products is dependent upon the extent to which we obtain rights under valid and enforceable

patents or trade secrets that cover these activities.

The patent positions of pharmaceutical and biopharmaceutical

companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved.

No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States.

biopharmaceutical patent situation outside the United States is even more uncertain.

Changes in either the patent laws or in interpretations

of patent laws in the United States and other countries may diminish the value of our intellectual property.

Accordingly, we cannot predict

the breadth of claims that may be allowed or enforced in the patents we own.

Further, if any of our patents are deemed invalid and unenforceable,

it could impact our ability to commercialize or license our technology.

The degree of future protection for our proprietary

rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain

or keep our competitive advantage.

● others may be able to make

products that are similar to our product candidates but that are not covered by the claims of any patents;

● we might not have been the

first to make the inventions covered by any issued patents or patent applications;

● we might not have been the

first to file patent applications for these inventions;

● it is possible that any patent

applications we own or license will not result in issued patents;

● any issued patents may not

provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;

● we may not develop additional

proprietary technologies that are patentable or protectable under trade secrets law;

● the patents of others may have

an adverse effect on our business.

We also may rely on trade secrets to protect our

technology, especially where we do not believe patent protection is appropriate or obtainable.

However, trade secrets are difficult to

Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific

collaborators, and other advisors may unintentionally or willfully disclose our information to competitors.

In addition, courts outside

the United States are sometimes less willing to protect trade secrets.

Moreover, our competitors may independently develop equivalent

knowledge, methods, and know-how.

We may be subject to claims challenging the

inventorship of patents and other intellectual property.

We or our licensors may be subject to claims

that former employees, collaborators or other third parties have an interest as an inventor or co-inventor in intellectual property

we own or license.

For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees,

consultants or others who are involved in developing our product candidates.

We may be subject to claims by third parties asserting

that our licensors, employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our

own intellectual property.

Litigation may be necessary to defend against these and other claims challenging inventorship or our or

our licensors’ ownership of our owned or in-licensed patents, trade secrets or other intellectual property.

licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property

rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates.

we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management

and other employees.

Any of the foregoing could have a material adverse effect on our business, financial condition, results of

operations and prospects.

If any of our trade secrets, know-how or other

proprietary information is disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired

and our business and competitive position would suffer.

Our viability also depends upon the skills, knowledge

and experience of our scientific and technical personnel, and our consultants and advisors.

To help protect our proprietary know-how and

our inventions for which patents may be unobtainable or difficult to obtain, we rely on trade secret protection and confidentiality agreements.

To this end, we require all of our employees, consultants, advisors and contractors to enter into agreements which prohibit unauthorized

disclosure and use of confidential information and, where applicable, require disclosure and assignment to us of the ideas, developments,

discoveries and inventions important to our business.

These agreements are often limited in duration and may not provide adequate protection

for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development

by others of such information.

There is no assurance that such agreements will be honored by such parties or enforced in whole or part

by the courts.

We cannot be certain that others will not gain access to these trade secrets or that our patents will provide adequate

Others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access

to our trade secrets.

In addition, enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive

and time consuming, and the outcome is unpredictable.

If any of our trade secrets, know-how or other proprietary information is improperly

disclosed, the value of our trade secrets, know-how and other proprietary rights would be significantly impaired and our business and

competitive position would suffer.

We may incur substantial costs as a result

of litigation or other proceedings relating to patent and other intellectual property rights and we may be unable to protect our rights

to, or use of, our technology.

If we choose to go to court to stop a third party

from using the inventions claimed in our patents, that individual or company has the right to ask the court to rule that such patents

are invalid and/or should not be enforced against that third party.

These lawsuits are expensive and would consume time and other resources,

even if we were successful in discontinuing the infringement of our patents.

In addition, there is a risk that the court will decide that

these patents are not valid and that we do not have the right to stop the other party from using the inventions.

There is also the risk

that, even if the validity of these patents is upheld, the court will refuse to stop the other party on the ground that such other party’s

activities do not infringe our rights to these patents.

In addition, the U.S.

Supreme Court has in the past invalidated tests used by

the USPTO in granting patents over the past 20 years.

As a consequence, issued patents may be found to contain invalid claims according

to the newly revised standards.

Some of our own patents may be subject to challenge and subsequent invalidation in a variety of post-grant

proceedings, particularly inter partes review, before the USPTO or during litigation under the revised criteria, which make it

more difficult to defend the validity of claims in already issued patents.

Furthermore, a third party may claim that we

or our manufacturing or commercialization partners are using inventions covered by the third party’s patent rights and may go

to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates.

lawsuits are costly and could affect our results of operations and divert the attention of managerial and technical personnel.

is a risk that a court could decide that we or our commercialization partners are infringing the third party’s patents and

order us or our partners to stop the activities covered by the patents.

In addition, there is a risk that a court could order us or

our partners to pay the other party damages for having violated the other party’s patents.

The biotechnology industry has

produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various

types of products, manufacturing processes or methods of use.

The coverage of patents is subject to interpretation by the courts,

and the interpretation is not always uniform.

If we are sued for patent infringement, we would need to demonstrate that our

products, manufacturing processes or methods of use either do not infringe the patent claims of the relevant patent and/or that the

patent claims are invalid, and we may not be able to do this.

Proving invalidity, in particular, is difficult since it requires a

showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents.

As some patent applications in the United States

may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions

are typically not published until eighteen months after filing, and because publications in the scientific literature often lag behind

actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our issued patents or

our pending applications, or that we were the first to invent the technology.

Our competitors may have filed, and may in the future file,

patent applications covering technology similar to ours.

Any such patent applications may have priority over our patent applications or

patents, which could further require us to obtain rights to issued patents covering such technologies.

If another party has filed a United

States patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO

to determine priority of invention in the United States.

The costs of these proceedings could be substantial, and it is possible that

such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior

to our own invention, resulting in a loss of our U.S.

patent position with respect to such inventions.

Some of our competitors may be able to sustain

the costs of complex patent litigation more effectively than we can because they have substantially greater resources.

In addition, any

uncertainties resulting from the initiation and continuation of any litigation or inter partes review proceedings could have a

material adverse effect on our ability to raise the funds necessary to continue our operations.

Some jurisdictions in which we operate have enacted

legislation which allows members of the public to access information under statutes similar to the U.S.

Freedom of Information Act.

though we believe our information would be excluded from the scope of such statutes, there are no assurances that we can protect our confidential

information from being disclosed under the provisions of such laws.

If any confidential or proprietary information is released to the

public, such disclosures may negatively impact our ability to protect our intellectual property rights.

Breaches or compromises of our information

security systems or our information technology systems or infrastructure could result in exposure of private information, disruption of

our business and damage to our reputation, which could harm our business, results of operation and financial condition.

We utilize information security and information

technology systems and websites that allow for the secure storage and transmission of proprietary or private information regarding our

clients, patients, employees, vendors and others, including individually identifiable health information.

A security breach of our network,

hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation and potential liability.

Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies

within the healthcare industry.

Although we believe that we take appropriate measures to safeguard sensitive information within our possession,

we may not have the resources or technical sophistication to anticipate or prevent rapidly-evolving types of cyber-attacks targeted at

us, our clients, our patients, or others who have entrusted us with information.

Actual or anticipated attacks may cause us to incur costs,

including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.

We invest in industry standard security technology to protect personal information.

Advances in computer capabilities, new technological

discoveries, or other developments may result in the technology used by us to protect personal information or other data being breached

or compromised.

To our knowledge, we have not experienced any material breach of our cybersecurity systems.

If our or our third-party

service provider systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning

to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could occur as a result

of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts of terrorism, circumvention

of security systems, or other cyber-attacks, we could experience delays or decreases in revenue, and reduced efficiency of our operations.

Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss, misappropriation or corruption

of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory actions, sanctions or other

statutory penalties, any or all of which could adversely affect our business, and cause us to incur significant losses and remediation

We may be exposed to liabilities under the

Foreign Corrupt Practices Act, and any determination that we violated the Foreign Corrupt Practices Act or Chinese anti-corruption law

could have a material adverse effect on our business.

We are subject to the Foreign Corrupt Practice

Act, or FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments and their officials and political

parties by U.S.

persons and issuers as defined by the statute, for the purpose of obtaining or retaining business.

We have operations

and agreements with third parties where corruption may occur.

It is our policy to implement safeguards to prevent these practices by our

However, our existing safeguards and any future improvements may prove to be less than effective, and the employees, consultants,

sales agents or distributors of our company may engage in conduct for which we might be held responsible.

Violations of the FCPA or other anti-corruption

laws may result in severe criminal or civil sanctions, and we may be subject to other liabilities, which could negatively affect our business,

operating results and financial condition.

In addition, the United States government may seek to hold our company liable for successor

liability FCPA violations committed by companies in which we invest or that we acquire.

Changes or disruption in services supplies,

or transportation provided by third parties have impacted and could continue to impact or adversely affect our business.

We depend on third parties to provide supplies and services critical

to our Keto Air business.

We are heavily reliant on third-party ground and air travel for transport of diagnostic testing supplies.

significant disruption to these travel systems, or our access to them, could have a material adverse effect on our business.

to the continued supply, or increases in costs, of these products.

may arise from export/import restrictions or embargoes, political or

economic instability, pressure from animal rights activists, adverse weather, natural disasters, public health crises, transportation

disruptions, cyber-attacks, or other causes, as well as from termination of relationships with suppliers or vendors for their failure

to follow our performance standards and requirements.

Disruption of supply and services has impacted and could continue to impact or have

a material adverse effect on our business related to the sale of Keto Air.

Risk Factors Related to Commercialization Activity

Some of our medical device products in the

future may face significant government regulation, and there is no guarantee that our medical devices will receive regulatory approval.

The manufacturing and marketing of our potential

medical device products such as our breathalyzer system may be subject to extensive regulation by the FDA and other regulatory authorities

in the United States, as well as by regulatory authorities in other countries.

In the United States, our product candidates are subject

to regulation as biological products or as combination biological products/medical devices under the Federal Food, Drug and Cosmetic Act,

the Public Health Service Act and other statutes, as outlined in the Code of Federal Regulations.

Different regulatory requirements may

apply to our products depending on how they are categorized by the FDA under these laws.

These regulations can be subject to substantial

and significant interpretation, addition, amendment or revision by the FDA and by the legislative process.

The FDA may determine that

we will need to undertake clinical trials beyond those currently planned.

Furthermore, the FDA may determine that results of clinical

trials do not support approval for the product.

Similar determinations may be encountered in foreign countries.

The FDA will continue

to monitor products in the market after approval, if any, and may determine to withdraw its approval or otherwise seriously affect the

marketing efforts for any such product.

The same possibilities exist for trials to be conducted outside of the United States that are

subject to regulations established by local authorities and local law.

Any such determinations would delay or deny the introduction of

our product candidates to the market and have a material adverse effect on our business, financial condition, and results of operations.

Certain medical devices are subject to ongoing

periodic unannounced inspection by the FDA, the Drug Enforcement Agency, other federal agencies and corresponding state agencies to ensure

strict compliance with good manufacturing practices, and other government regulations and corresponding foreign standards.

We do not have

control over third-party manufacturers’ compliance with these regulations and standards, nor can we guarantee that we will maintain

compliance with such regulations in regard to our own manufacturing processes.

Other risks include:

● regulatory authorities may

require the addition of labeling statements, specific warnings, a contraindication, or field alerts to physicians and pharmacies;

● regulatory authorities may

withdraw their approval of the IND or the product or require us to take our approved products off the market;

● we may be required to change

the way the product is manufactured or administered and we may be required to conduct additional clinical trials or change the labeling

of our products;

● we may have limitations on

how we promote our products;

● we may be subject to litigation

or product liability claims.

Even if our medical devices receive regulatory

approval in the United States, we may never receive approval or commercialize our product candidates outside of the United States.

order to market and commercialize any product candidate outside of the United States, we must establish and comply with numerous and varying

regulatory requirements of other countries regarding manufacturing, safety and efficacy.

Approval procedures vary among countries and

can involve additional product testing and additional administrative review periods.

The time required to obtain approval in other countries

might differ from that required to obtain FDA approval.

The regulatory approval process in other countries may include all of the risks

detailed above regarding FDA approval in the United States as well as other risks.

Regulatory approval in one country does not ensure

regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the

regulatory approval process in others.

Failure to obtain regulatory approval in other countries, or any delay or setback in obtaining

such approval, could have the same adverse effects detailed above regarding FDA approval in the United States.

Such effects include the

risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates

and have an adverse effect on product sales and potential royalties, and that such approval may be subject to limitations on the indicated

uses for which the product may be marketed or require costly, post-marketing follow-up studies.

Even if our medical devices receive regulatory

approval, we may still face future development and regulatory difficulties.

regulatory approval is obtained,

the FDA may still impose significant restrictions on a product’s indicated uses or marketing, or impose ongoing requirements for

potentially costly post-approval studies.

If any of our products were granted accelerated approval, FDA could require post-marketing confirmatory

trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit.

FDA may withdraw

approval of a drug or indication approved under the accelerated approval pathway if a trial required to verify the predicted clinical

benefit of the product fails to verify such benefit;

other evidence demonstrates that the product is not shown to be safe or effective

under the conditions of use;

the applicant fails to conduct any required post-approval trial of the drug with due diligence;

or the applicant

disseminates false or misleading promotional materials relating to the product.

In addition, the FDA currently requires as a condition

for accelerated approval the pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of

Given the number of recent high-profile adverse safety events with

certain medical devices, the FDA may require, as a condition of approval, costly risk management programs, which may include safety surveillance,

restricted distribution and use, patient education, enhanced labeling, special packaging or labeling, expedited reporting of certain adverse

events, pre-approval of promotional materials, and restrictions on direct-to-consumer advertising.

Furthermore, heightened Congressional

scrutiny on the adequacy of the FDA’s drug approval process and the FDA’s efforts to assure the safety of marketed cell based

therapy has resulted in the proposal of new legislation addressing drug safety issues.

If enacted, any new legislation could result in

delays or increased costs during the period of product development, and regulatory review and approval, as well as increased

costs to assure compliance with any new post-approval regulatory requirements.

Any of these restrictions or requirements could force us

to conduct costly studies or increase the time for us to become profitable.

For example, any labeling approved for any of our product

candidates may include a restriction on the term of its use, or it may not include one or more of our intended indications.

Our product candidates will also be subject to

ongoing FDA requirements for the labeling, packaging, storage, advertising, promotion, record-keeping, and submission of safety and other

post-market information on the cell based therapy.

New issues may arise during a product lifecycle that did not exist, or were unknown,

at the time of product approval, such as adverse events of unanticipated severity or frequency, or problems with the facility where the

product is manufactured.

Since approved products, manufacturers, and manufacturers’ facilities are subject to continuous review

and periodic inspections, these new issues post-approval may result in voluntary actions by us or may result in a regulatory agency imposing

restrictions on that product or us, including requiring withdrawal of the product from the market or for use in a clinical study.

product candidates fail to comply with applicable regulatory requirements, such as good manufacturing practices, a regulatory agency may:

issue warning letters;

require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions, and penalties for noncompliance;

impose other civil or criminal penalties;

suspend regulatory approval;

suspend any ongoing clinical trials;

refuse to approve pending applications or supplements to approved applications filed by us;

impose restrictions on operations, including costly new manufacturing requirements;

seize or detain products or require a product recall.

If we or current or future collaborators, manufacturers,

or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions and substantial

penalties, which could affect our ability to develop, market and sell our products and may harm our reputation.

Although we currently are only marketing Keto Air, once our medical

devices are covered by federal health care programs, we will be subject to additional healthcare statutory and regulatory requirements

and enforcement by the federal, state and foreign governments of the jurisdictions in which we conduct our business.

Healthcare providers,

physicians and third party payors play a primary role in the recommendation and prescription of any medical devices for which we obtain

marketing approval.

Our future arrangements with third party payors and customers may expose us to broadly applicable fraud and abuse,

transparency, and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through

which we market, sell and distribute our therapeutic candidates for which we obtain marketing approval.

Restrictions under applicable

federal and state healthcare laws and regulations include, but are not limited to, the following:

federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare or Medicaid;

federal civil and criminal false claims laws and civil monetary penalty laws, such as the U.S.

federal FCA, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against, individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government.

In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;

HIPAA includes a fraud and abuse provision referred to as the HIPAA All-Payor Fraud Law, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.

Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

HIPAA, as amended by HITECH, and its implementing regulations, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding, the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;

federal and state consumer protection and unfair competition laws,

which broadly regulate marketplace activities and activities that potentially harm consumers;

the federal Physician Payment Sunshine Act and the implementing regulations, also referred to as “Open Payments,” issued under the ACA, which require that manufacturers of pharmaceutical and biological drugs reimbursable under Medicare, Medicaid, and Children’s Health Insurance Programs report to the Department of Health and Human Services all consulting fees, travel reimbursements, research grants, and other payments, transfers of value or gifts made to physicians and teaching hospitals with limited exceptions;

The scope and enforcement of each of these laws

is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable

precedent and regulations.

Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare

companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare

Responding to investigations can be time-and resource-consuming and can divert management’s attention from the business.

Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business.

Ensuring that our business arrangements with third-parties

comply with applicable healthcare laws and regulations could involve substantial costs.

If our operations are found to be in violation

of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or

restructuring of our operations, or exclusion from participation in government contracting, healthcare reimbursement or other government

programs, including Medicare and Medicaid, any of which could adversely affect our financial results.

Although effective compliance programs

can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated.

against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management’s

attention from the operation of our business, even if our defense is successful.

In addition, achieving and sustaining compliance with

applicable laws and regulations may be costly to us in terms of money, time and resources.

Any medical devices we develop may become subject

to unfavorable pricing regulations, third party coverage and reimbursement practices or healthcare reform initiatives, thereby harming

our business.

The regulations that govern marketing

approvals, pricing, coverage and reimbursement for new medical devices vary widely from country to country.

Some countries require

approval of the sale price of a device before it can be marketed.

In many countries, the pricing review period begins after

marketing or product licensing approval is granted.

In some foreign markets, prescription pharmaceutical pricing remains subject to

continuing governmental control even after initial approval is granted.

Although we intend to monitor these regulations, our

programs are currently in earlier stages of development and we will not be able to assess the impact of price regulations for a

number of years.

As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to

price regulations that delay our commercial launch of the product and negatively impact the revenues we are able to generate from

the sale of the product in that country.

Our ability to commercialize any products successfully also will depend

in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government

health administration authorities, private health insurers and other organizations.

However, there may be significant delays in obtaining

coverage for newly-approved medical devices.

Moreover, eligibility for coverage does not necessarily signify that a cell based therapy

will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution

Also, interim payments for new cell based therapy if applicable, may be insufficient to cover our costs and may not be made permanent.

Thus, even if we succeed in bringing one or more products to the market, these products may not be considered medically necessary

or cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis.

Because our programs are in earlier stages of development, we are unable at this time to determine their cost effectiveness, or the likely

level or method of reimbursement.

In addition, obtaining coverage and reimbursement approval of a product from a government or other third-party

payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness

data for the use of our product on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained.

A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.

one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the

Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate

return on our investment in product development.

If reimbursement is not available or is available only at limited levels, we may not

be able to successfully commercialize any product candidate that we successfully develop.

Increasingly, the third party payors who reimburse

patients or healthcare providers, such as government and private insurance plans, are seeking greater upfront discounts, additional rebates

and other concessions to reduce the prices for pharmaceutical products.

If the price we are able to charge for any products we develop,

or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could

be adversely affected.

the product is reasonable and necessary for the diagnosis or treatment of the illness or injury for which the product is administered according to accepted standards of medical practice;

the product is typically furnished incident to a physician’s services;

the indication for which the product will be used is included or approved for inclusion in certain Medicare-designated pharmaceutical compendia (when used for an off-label use);

the product has been approved by the FDA.

Average prices for medical devices may be reduced by mandatory discounts

or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports

of medical devices from countries where they may be sold at lower prices than in the U.S.

Reimbursement rates under Medicare Part B would

depend in part on whether the newly approved product would be eligible for a unique billing code.

It is difficult for us to predict how

Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and reimbursement under different

federal healthcare programs are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints placed on the

Medicare program.

Third party payors often rely upon Medicare coverage policies and payment

limitations in setting their own reimbursement rates.

These coverage policies and limitations may rely, in part, on compendia listings

for approved therapeutics.

Our inability to promptly obtain relevant compendia listings, coverage, and adequate reimbursement from both

government-funded and private payors for products that we develop and for which we obtain regulatory approval could have a material adverse

effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.

We expect that these and other healthcare reform measures that may

be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on

the price that we receive for any approved product.

Any reduction in reimbursement from Medicare or other government-funded programs may

result in a similar reduction in payments from private payors.

The implementation of cost containment measures or other healthcare reforms

may prevent us from being able to generate revenue, attain profitability or commercialize our products, once marketing approval is obtained.

We believe that the efforts of governments and

third party payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of

healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies.

legislative and regulatory changes in the healthcare system in the U.S.

and other major healthcare markets have been proposed, and such

efforts have expanded substantially in recent years.

These developments could, directly or indirectly, affect our ability to sell our

products, if approved, at a favorable price.

For example, in the United States, in 2010, the U.S.

Congress passed the ACA, a sweeping

law intended to broaden access to health insurance, reduce or constrain the growth of health spending, enhance remedies against fraud

and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health

industry and impose additional policy reforms.

Among the provisions of the ACA addressing coverage and reimbursement of pharmaceutical

products, of importance to our potential therapeutic candidates are the following:

Separately, pursuant to the health reform legislation

and related initiatives, the Centers for Medicare and Medicaid Services, or CMS, is working with various healthcare providers to develop,

refine, and implement Accountable Care Organizations, or ACOs, and other innovative models of care for Medicare and Medicaid beneficiaries,

including the Bundled Payments for Care Improvement Initiative, the Comprehensive Primary Care Initiative, the Duals Demonstration, and

other models.

The continued development and expansion of ACOs and other innovative models of care will have an uncertain impact on any

future reimbursement we may receive for approved therapeutics administered by these organizations.

The healthcare industry is heavily regulated

at the federal, state, and local levels, and our failure to comply with applicable requirements may subject us to penalties

and negatively affect our financial condition.

As a healthcare company, our operations and interactions

with healthcare providers may be subject to extensive regulation in the U.S., particularly if we receive FDA approval for any of its products

in the future.

For example, if we receive FDA approval for a product for which reimbursement is available under a federal healthcare program

(e.g., Medicare, Medicaid), it would be subject to a variety of federal laws and regulations, including those that prohibit the filing

of false or improper claims for payment by federal healthcare programs (e.g.

the federal False Claims Act), prohibit unlawful inducements

for the referral of business reimbursable by federal healthcare programs (e.g.

the federal Anti-Kickback Statute), and require disclosure

of certain payments or other transfers of value made to U.S.-licensed physicians and teaching hospitals or Open Payments.

We are not able

to predict how third parties will interpret these laws and apply applicable governmental guidance and may challenge our practices and

activities under one or more of these laws.

If our past or present operations are found to be in violation of any of these laws, we could

be subject to civil and criminal penalties, which could hurt our business, our operations and financial condition.

The federal Anti-Kickback Statute prohibits,

among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration,

directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or

arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare

The term remuneration has been interpreted broadly to include anything of value.

The Anti-Kickback Statute has been

interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary

managers on the other.

There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from

The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be

intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or

Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does

not make the conduct per se illegal under the Anti-Kickback Statute.

Instead, the legality of the arrangement will be evaluated on a

case-by-case basis based on a cumulative review of all of its facts and circumstances.

Our practices may not in all cases meet all

of the criteria for protection under a statutory exception or regulatory safe harbor.

Additionally, the intent standard under the Anti-Kickback

Statute was amended by the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute

or specific intent to violate it in order to have committed a violation.

In addition, the ACA codified case law that a claim including

items or services resulting from a violation of the federal Anti- Kickback Statute constitutes a false or fraudulent claim for purposes

of the federal FCA.

The civil monetary penalties statute imposes penalties

against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal

healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.

Federal false claims and false statement laws,

including the federal FCA, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a

false or fraudulent claim for payment to, or approval by, the federal healthcare programs, including Medicare and Medicaid, or knowingly

making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government.

A claim includes “any request or demand” for money or property presented to the U.S.

For instance, historically,

pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers

with the expectation that the customers would bill federal programs for the product.

Other companies have been prosecuted for causing

false claims to be submitted because of the companies’ marketing of the product for unapproved, off-label, and thus generally non-reimbursable,

HIPAA prohibits, among other offenses, knowingly

and willfully executing a scheme to defraud any health care benefit program, including private payors, or falsifying, concealing or covering

up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for

items or services under a health care benefit program.

To the extent that we act as a business associate to a healthcare provider engaging

in electronic transactions, we may also be subject to the privacy and security provisions of HIPAA, as amended by HITECH, which restricts

the use and disclosure of patient-identifiable health information, mandates the adoption of standards relating to the privacy and security

of patient-identifiable health information, and requires the reporting of certain security breaches to healthcare provider customers with

respect to such information.

Additionally, many states have enacted similar laws that may impose more stringent requirements on entities

Failure to comply with applicable laws and regulations could result in substantial penalties and adversely affect our financial

condition and results of operations.

Many states also have similar fraud and abuse

statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply

regardless of the payor.

Additionally, to the extent that our product is sold in a foreign country, we may be subject to similar foreign

Our products, once approved, may be eligible

for coverage under Medicare and Medicaid, among other government healthcare programs.

Accordingly, we may be subject to a number of

obligations based on their participation in these programs, such as a requirement to calculate and report certain price reporting

metrics to the government, such as average sales price (ASP) and best price.

Penalties may apply in some cases when such metrics are

not submitted accurately and timely.

Further, these prices for medical devices may be reduced by mandatory discounts or rebates

required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of

medical devices from countries where they may be sold at lower prices than in the United States.

It is difficult to predict how

Medicare coverage and reimbursement policies will be applied to our products in the future and coverage and reimbursement under

different federal healthcare programs are not always consistent.

Medicare reimbursement rates may also reflect budgetary constraints

placed on the Medicare program.

In order to distribute products commercially, we must comply with state

laws that require the registration of manufacturers and wholesale distributors of medical devices in a state, including, in certain states,

manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within

Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of

distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product

as it moves through the distribution chain.

Several states have enacted legislation requiring pharmaceutical and biotechnology companies

to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,

pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other

healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and

marketing, and to prohibit certain other sales and marketing practices.

All of our activities are potentially subject to federal and state

consumer protection and unfair competition laws.

If our operations are found to be in violation

of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject

to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from

participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by individual

whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational

harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which

could adversely affect our ability to operate our business and our results of operations.

Our ability to obtain reimbursement or funding

from the federal government may be impacted by possible reductions in federal spending.

federal government agencies currently face

potentially significant spending reductions.

The Budget Control Act of 2011, or the BCA, established a Joint Select Committee on Deficit

Reduction, which was tasked with achieving a reduction in the federal debt level of at least $1.2 trillion.

That committee did not draft

a proposal by the BCA’s deadline.

As a result, automatic cuts, referred to as sequestration, in various federal programs were scheduled

to take place, beginning in January 2013, although the American Taxpayer Relief Act of 2012 delayed the BCA’s automatic cuts until

March 1, 2013.

While the Medicare program’s eligibility and scope of benefits are generally exempt from these cuts, Medicare payments

to providers and Part D health plans are not exempt.

The BCA did, however, provide that the Medicare cuts to providers and Part D health

plans would not exceed two percent.

President Obama issued the sequestration order on March 1, 2013, and cuts went into effect on April

Additionally, the Bipartisan Budget Act of 2015 extended sequestration for Medicare through fiscal year 2027.

federal budget remains in flux, which

could, among other things, cut Medicare payments to providers.

The Trump Administration cost reduction initiatives may impact Medicare

and Medicaid reimbursement levels.

Medicare program is frequently mentioned as a target for spending cuts.

The full impact on our business

of any future cuts in Medicare or other programs is uncertain.

In addition, we cannot predict any impact President Trump’s administration

Congress may have on the federal budget.

If federal spending is reduced, anticipated budgetary shortfalls may also impact

the ability of relevant agencies, such as the FDA or the National Institutes of Health, to continue to function at current levels.

allocated to federal grants and contracts may be reduced or eliminated.

These reductions may also impact the ability of relevant agencies

to timely review and approve medical devises and development, manufacturing, and marketing activities, which may delay our ability to

develop, market and sell any products we may develop.

Risks Related to Our Securities

Our officers, directors and principal stockholders

own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Our officers, directors and 5% stockholders

and their affiliates beneficially own a significant percentage of our outstanding common stock.

As a result, these stockholders have

significant influence and may be able to determine all matters requiring stockholder approval.

For example, these stockholders may

be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or

other major corporate transactions.

This concentration of ownership could delay or prevent any acquisition of our company on terms

that other stockholders may desire, and may adversely affect the market price of our common stock.

If we are unable to

maintain listing of our securities on The Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for our

stockholders to sell their securities.

Nasdaq requires listing

issuers to comply with certain standards in order to remain listed on its exchange.

If Nasdaq should delist our securities from trading

on its exchange for any reason and we are unable to obtain listing on another reputable national securities exchange, a reduction in some

or all of the following may occur, each of which could materially adversely affect our stockholders.

A delisting of our common stock is

likely to reduce the liquidity of our common stock and may inhibit or preclude our ability to raise additional financing.

The price of our common stock may be volatile

and fluctuate substantially, which could result in substantial losses for our stockholders.

Our common stock is listed on the Nasdaq Capital

Market under the symbol “ALBT.” The price of our common stock has been, and we expect it to continue to be, volatile.

stock market in general and the market for smaller healthcare companies in particular have experienced extreme volatility that has often

been unrelated to the operating performance of particular companies.

As a result of this volatility, you may not be able to sell your

shares of common stock at or above the price you paid for your shares of common stock.

The market price for our common stock may be influenced

by many factors, including:

the success of competitive products or technologies;

developments related to our existing or any future collaborations;

regulatory or legal developments in the United States and other countries;

developments or disputes concerning patent applications, issued patents or other proprietary rights;

the recruitment or departure of key personnel;

actual or anticipated changes in estimates as to financial results or recommendations by securities analysts;

variations in our financial results or those of companies that are perceived to be similar to us;

changes in the structure of healthcare payment systems;

market conditions in the healthcare, pharmaceutical and biotechnology sectors;

general economic, industry and market conditions;

the other factors described in this “Risk Factors” section.

Future sales of our common stock or securities

convertible or exchangeable for our common stock may cause our stock price to decline.

If our existing stockholders sell, or indicate

an intention to sell, substantial amounts of our common stock in the public market, the price of our common stock could decline.

The perception

in the market that these sales may occur could also cause the price of our common stock to decline.

In addition, as of December 31, 2024:

shares of our common stock were issuable upon exercise of outstanding stock options;

shares of our common stock were issuable upon exercise of outstanding stock warrants;

shares of our common stock issuable upon conversion of our outstanding Series A Preferred

shares of our common stock were issuable upon the conversion of our outstanding Series B

Convertible Preferred Stock (the “Series B Preferred Stock”), which will become

eligible for sale in the public market to the extent permitted by the provisions of various

vesting schedules, lock-up agreements and Rule 144 under the Securities Act;

shares of our common stock issuable upon conversion of our outstanding Series C Preferred

shares of our common stock issuable upon conversion of our outstanding convertible notes.

If the shares we may issue from time to time upon

the exercise of outstanding options and warrants and the conversion of our outstanding Series C Preferred Stock and Series D Preferred

Stock are sold and outstanding convertible notes are issues, or if it is perceived that they will be sold, by the award recipients in

the public market, the price of our common stock could decline.

You may experience dilution of your ownership

interests because of the future issuance of additional shares of our common or preferred stock or other securities that are convertible

into or exercisable for our common or preferred stock.

As of the date of this filing, we have issued

an aggregate of (i) 3,500 shares of our newly designated Series C Preferred Stock and (ii) 5,000 shares of our newly designated Series

D Preferred Stock.

In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of

the ownership interests of our stockholders.

We are authorized to issue an aggregate of 100,000,000 shares of common stock and 10,000,000

shares of “blank check” preferred stock.

We may issue additional shares of our common stock or other securities that are convertible

into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities

for capital raising purposes, or for other business purposes.

The future issuance of any such additional shares of our common stock may

create downward pressure on the trading price of our common stock.

We expect we will need to raise additional capital in the near future

to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or

other convertible securities in the future in conjunction with these capital raising efforts, including at a price (or exercise prices)

below the price you paid for your stock.

The ability of our Board to issue additional

stock may prevent or make more difficult certain transactions, including a sale or merger.

Our Board is authorized to issue up to 10,000,000

shares of preferred stock with powers, rights and preferences designated by it.

Shares of voting or convertible preferred stock could

be issued, or rights to purchase such shares could be issued, to create voting impediments or to frustrate persons seeking to effect a

takeover or otherwise gain control of us.

The rights of holders of our common stock are subject to the rights of the holders of our preferred

stock, including our newly designated Series D Preferred Stock, Series D Preferred Stock and any preferred stock that may be issued.

ability of the Board to issue such additional shares of preferred stock, with rights and preferences it deems advisable, could discourage

an attempt by a party to acquire control of us by tender offer or other means.

Such issuances could therefore deprive stockholders of

benefits that could result from such an attempt, such as the realization of a premium over the market price for their shares in a tender

offer or the temporary increase in market price that such an attempt could cause.

Moreover, the issuance of such additional shares of

preferred stock to persons friendly to the Board could make it more difficult to remove incumbent managers and directors from office even

if such change were to be favorable to stockholders generally.

We are incorporated in Delaware.

Certain anti-takeover

provisions of Delaware law and our charter documents as currently in effect may make a change in control of us more difficult, even if

a change in control would be beneficial to the stockholders.

Patent applications may not result in issued patents, and even if issued, they

may not provide meaningful protection.

The Leahy-Smith America Invents Act introduced procedures that may make it easier for third parties

to challenge issued patents.

Filing, prosecuting, and defending patents in all countries would be prohibitively expensive, and intellectual

property rights in some countries outside the United States may be less extensive.

We have filed three provisional patent applications

in connection with our RPM platform, and there can be no assurance that any patents will issue from these applications, or that any issued

patents will provide meaningful competitive protection.

Additionally, certain patents in our cellular therapy portfolio are co-owned with

MIT and Arbelli, and our ability to license or enforce such patents unilaterally may be limited by the terms of our co-ownership arrangements.

Laws and regulations governing artificial

intelligence are rapidly evolving, and compliance may be costly and uncertain.

Laws and regulations affecting AI are continually

Compliance with new laws can be costly and time-consuming, and we could be subject to regulatory enforcement actions or litigation

if we fail to comply.

There is substantial uncertainty about the nature, direction, severity, and granularity of future AI regulation.

Government bodies have implemented laws and are considering further regulating AI and machine learning, which could negatively impact

our ability to use these technologies.

New and changed rules regarding privacy, data protection, and cross-border transfers of customer

information could cause us to delay planned uses and disclosures of data.

The European Union's Artificial Intelligence Act, which entered

into force in 2024, may impose specific obligations on AI systems that generate synthetic media depicting real individuals.

To the extent

our platform is accessed by users in the European Union, we may become subject to these obligations, compliance with which could require

significant operational and legal resources.

Our platform's content may be restricted

or removed by major social media and content distribution platforms, which could significantly impair the utility and commercial appeal

of our product.

The RPM platform is designed to generate content

for distribution across major social media and content platforms, including YouTube, TikTok, Instagram, and others.

Each of these platforms

maintains content policies governing the disclosure and permissibility of AI-generated content, synthetic media, and avatar-based representations

of real individuals.

These policies are subject to frequent revision and vary across platforms.

Failure to comply with applicable platform

content policies could result in the removal of content generated through our platform, the suspension or termination of creator accounts

on those platforms, or other restrictions that could adversely affect the utility and commercial appeal of our platform to content creators,

and in turn our ability to generate revenue.

Our business depends on the reliable performance

of third-party cloud and infrastructure providers, and any disruption to these services could adversely affect our operations.

We intend to rely on third-party providers for

computing infrastructure, secure network connectivity, and other technology-related services.

Any disruption in services provided by such

third-party providers could adversely affect our business.

These providers may take actions beyond our control, including discontinuing

or limiting access to their cloud platform, increasing pricing terms, terminating contractual relationships, or establishing more favorable

relationships with our competitors.

Cybersecurity breaches or incidents could

damage our reputation and adversely affect our business.

Security breaches and attacks against our systems

and network could damage our reputation and negatively impact our business.

As a small company with limited resources, our cybersecurity

measures may not detect or prevent all attempts to compromise our systems, including distributed denial-of-service attacks, viruses, malicious

software, phishing attacks, and social engineering.

Breaches could result in unauthorized access, misappropriation of information, deletion

or modification of user or consumer information, or denial-of-service interruptions.

Our current data footprint is limited — consisting

primarily of email communications, consumer purchase data collected through Keto Air sales, and content creator data gathered through

our limited RPM beta program — but will expand significantly as our platform scales commercially.

Any material cybersecurity incident

could adversely affect our reputation, expose us to regulatory enforcement, and result in significant costs.

We are subject to data privacy and security

laws that impose significant compliance obligations, and any failure to comply could result in material liability.

We are subject to laws and regulations concerning

privacy, information security, data protection, consumer protection, and protection of minors, including the California Consumer Privacy

Act, as amended by the California Privacy Rights Act, and similar state laws.

Compliance has required significant operational resources

and expenses.

Any failure or perceived failure to comply with privacy-related obligations may result in governmental enforcement actions,

investigations, litigation, or public statements against us, and could cause users to lose trust in our products and services.

The collection

and processing of voice and likeness data through our RPM platform's avatar generation feature may also implicate obligations under applicable

biometric data privacy laws, including the Illinois Biometric Information Privacy Act and similar state statutes, and we are continuing

to evaluate our compliance obligations in this area.

Risks Relating to Our Capital Structure and

Nasdaq Listing

We will need to raise additional capital

to fund our operations and growth, and we may not be able to do so on acceptable terms, or at all.

We are currently operating at a loss and expect

our operating costs to increase significantly.

As of December 31, 2025, we had cash from continuing operations of approximately $0.1 million.

We will need to raise additional capital or generate substantial revenue to support our development and commercialization efforts.

have no arrangements or credit facilities currently in place as a source of funds, and there can be no assurance that we will be able

to raise sufficient additional capital on acceptable terms, or at all.

If we are unable to raise additional capital as needed, we may

be required to curtail or cease our operations, delay or reduce the scope of our development activities, or relinquish rights to certain

of our assets or technologies.

We have outstanding indebtedness that could

adversely affect our financial condition and liquidity.

As of December 31, 2025, we had approximately

$1.1 million of outstanding indebtedness (excluding $5.8 million of outstanding indebtedness from discontinued operations).

unable to generate sufficient cash to repay our debt obligations when they become due, we may not be able to obtain additional debt or

equity financing on favorable terms.

If we breach any undertakings or default on any obligations under our agreements with lenders, our

outstanding indebtedness could become immediately due and payable.

Future sales and issuances of our securities

could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.

We expect that significant additional capital will be needed in the future to continue our planned operations,

including research and development, increased marketing, hiring new personnel, commercializing our products, and continuing activities

as an operating public company.

To the extent we raise additional capital by issuing equity securities, our stockholders may experience

substantial dilution.

We may sell common stock, convertible securities or other equity securities in one or more transactions at prices

and in a manner we determine from time to time.

If we sell common stock, convertible securities or other equity securities in more than

one transaction, investors may be materially diluted by subsequent sales.

Such sales may also result in material dilution to our existing

stockholders, and new investors could gain rights superior to our existing stockholders.

Future issuances of our securities, including

upon conversion of our outstanding preferred stock, will dilute the ownership interests of our existing stockholders and may depress the

trading price of our common stock.

Stockholders may experience dilution of their

ownership interests because of the future issuance of additional shares of our common or preferred stock or other securities that are

convertible into or exercisable for common or preferred stock.

As of the date of filing, we have issued 3,800 shares of Series C Preferred

Stock, 5,000 shares of Series D Preferred Stock, and 19,500 shares of Series E Preferred Stock.

The future issuance of any such additional

shares may create downward pressure on the trading price of our common stock.

As of December 31, 2025, we had:

41,169 shares issuable

upon exercise of outstanding stock options;

95,746 shares issuable upon exercise of outstanding stock warrants;

1,576,763 shares issuable

upon conversion of outstanding Series C Preferred Stock;

2,074,689 shares issuable upon conversion of outstanding Series D Preferred Stock;

13,000,000 shares issuable upon conversion of outstanding Series E Preferred Stock;

and 788,283 shares issuable upon conversion of outstanding

convertible notes and related accrued interest.

If these shares are sold or perceived to be sold in the public market, the price of our

common stock could decline.

Our Series E Non-Voting Convertible Preferred

Stock is subject to an Exchange Cap and requires stockholder approval under Nasdaq Listing Rule 5635 prior to conversion, and there can

be no assurance that we will obtain such approval.

Our Series E Preferred Stock is convertible into

shares of our common stock at a conversion price of $1.50 per share, subject to:

(i) a beneficial ownership cap of 4.99% applicable to

(ii) an Exchange Cap that prevents the issuance of shares of common stock upon conversion in excess of the number of shares

we may issue without breaching our obligations under applicable Nasdaq listing rules and regulations;

and (iii) the receipt of stockholder

approval in accordance with Nasdaq Listing Rule 5635.

We intend to seek this stockholder approval at our annual meeting of stockholders

currently scheduled to be held on or before May 12, 2026.

There can be no assurance that our stockholders will approve the conversion

of the Series E Preferred Stock.

If such approval is not obtained, the Series E Preferred Stock will remain unconverted, which could adversely

affect our ability to raise additional capital, may require us to redeem the Series E Preferred Stock, and could have a material adverse

effect on our business and financial condition.

We must maintain compliance with Nasdaq

continued listing standards, and there can be no assurance that we will be able to do so.

We are required to comply with certain Nasdaq

rules including those regarding minimum stockholders' equity, minimum share price, and certain corporate governance requirements.

fail to comply with these rules and are delisted, we could face significant consequences including limited availability of market quotations,

reduced liquidity, a determination that our common stock is a "penny stock," limited news and analyst coverage, and a decreased

ability to issue additional securities or obtain additional financing.

We previously received a deficiency notice from Nasdaq relating

to our minimum stockholders' equity, and while we believe the completion of the RPM acquisition has resolved that deficiency, there can

be no assurance that Nasdaq will confirm such resolution or that we will not face future listing deficiencies.

If we are unable to maintain

listing of our securities on The Nasdaq Capital Market or another reputable stock exchange, it may be more difficult for stockholders

to sell their securities, and a delisting is likely to reduce the liquidity of our common stock and may inhibit or preclude our ability

to raise additional financing.

Significant related party transactions,

including the sale of our Route 9 property to a director, create conflicts of interest and could adversely affect stockholder confidence

in our corporate governance.

On February 18, 2026, we completed the sale of

100% of the membership interests of Avalon RT 9 Properties, LLC to Wenzhao Lu, the Chairman of our Board of Directors, for a total aggregate

purchase price of approximately $9,000,000.

This transaction, as well as other related party transactions in our history — including

the exchange of Series A Preferred Stock for Series D Preferred Stock by our Chairman — involve members of our board of directors

or their affiliates.

Although all such transactions have been reviewed and approved by our Board of Directors, with the participation

of disinterested directors, and in accordance with our related party transaction policy, related party transactions present inherent conflicts

of interest and could adversely affect stockholder confidence in our corporate governance practices and the integrity of our financial

Our officers, directors, and significant

stockholders collectively hold a significant percentage of our outstanding common stock, which may limit the ability of other stockholders

to influence corporate decisions.

Our officers, directors, and 5% stockholders and

their affiliates beneficially own a significant percentage of our outstanding common stock.

As a result, these stockholders have significant

influence and may be able to determine all matters requiring stockholder approval, including elections of directors, amendments of our

organizational documents, or approval of any merger, sale of assets, or other major corporate transactions.

This concentration of ownership

may make it difficult for other stockholders to influence significant corporate decisions, may discourage potential acquirors from pursuing

a business combination with us, and may have a depressive effect on the trading price of our common stock.

Provisions in our charter documents and

Delaware law may have anti-takeover effects that could prevent a change of control that stockholders may consider favorable.

Our Board of Directors is authorized to issue

up to 10,000,000 shares of preferred stock with powers, rights, and preferences designated by it, which could be used to create voting

impediments or frustrate persons seeking to effect a takeover.

Delaware law also prohibits corporations from engaging in a business combination

with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless, among other possibilities,

our Board approves the transaction.

Our Board may use these provisions to prevent changes in the management and control of us.

applicable Delaware law, our Board may adopt additional anti-takeover measures in the future.

If securities or industry analysts do not publish

research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading

volume could decline.

The trading market for our common stock will be

influenced by the research and reports that industry or securities analysts publish about us or our business.

We do not currently have

and may never obtain research coverage by securities and industry analysts.

If no or few securities or industry analysts commence coverage

of us, the trading price for our stock would be negatively impacted.

In the event we obtain securities or industry analyst coverage, if

any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or

our stock performance, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline.

one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial

markets, which in turn could cause our stock price or trading volume to decline.

We do not anticipate paying dividends on our

common stock, and investors may lose the entire amount of their investment.

We have never declared or paid cash dividends

on our common stock, and we do not anticipate such a declaration or payment for the foreseeable future.

We expect to use future earnings, if any, to fund

business growth.

Therefore, stockholders will not receive any funds absent a sale of their shares of our common stock.

We cannot assure

stockholders of a positive return on their investment when they sell their shares, nor can we assure that stockholders will not lose the

entire amount of their investment.

Applicable regulatory requirements, including

those contained in and issued under the Sarbanes-Oxley Act of 2002, may make it difficult for us to retain or attract qualified officers

and directors, which could adversely affect the management of our business and our ability to obtain or retain listing of our common stock

on a national securities exchange.

We may be unable to attract and retain those qualified

officers, directors and members of board committees required to provide for effective management because of the rules and regulations

that govern publicly held companies, including, but not limited to, certifications by principal executive officers.

The enactment of the

Sarbanes-Oxley Act has resulted in the issuance of a series of related rules and regulations and the strengthening of existing rules and

regulations by the SEC, as well as the adoption of new and more stringent rules by national securities exchanges.

The perceived increased

personal risk associated with these changes may deter qualified individuals from accepting roles as directors and executive officers.

Further, some of these changes heighten the requirements

for board or committee membership, particularly with respect to an individual’s independence from the corporation and level of experience

in finance and accounting matters.

We may have difficulty attracting and retaining directors with the requisite qualifications.

are unable to attract and retain qualified officers and directors, the management of our business and our ability to obtain or retain

listing of our shares of common stock on any national securities exchange could be adversely affected.

If we cannot satisfy the continued listing

requirements and other rules of The Nasdaq Capital Market, our securities may be delisted, which could negatively impact the price of

our securities and your ability to sell them.

Our common stock is listed on The Nasdaq Capital

Market under the symbol “ALBT.” In order to maintain our listing on The Nasdaq Capital Market, we are required to comply with

certain rules of the applicable trading market, including those regarding minimum stockholders’ equity, minimum share price and

certain corporate governance requirements.

We may not be able to continue to satisfy the listing requirements and other applicable rules

of The Nasdaq Capital Market.

If we are unable to satisfy the criteria for maintaining our listing, our securities could be subject to

If our common stock is delisted from trading by

the applicable trading market we could face significant consequences, including.

● a limited availability for

market quotations for our securities;

● reduced liquidity with respect

to our securities;

● a determination that our common

stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly

result in a reduced level of trading activity in the secondary trading market for our common stock;

● limited amount of news and

analyst coverage;

● a decreased ability to issue

additional securities or obtain additional financing in the future.

We could be subject to securities class action

In the past, securities class action litigation

has often been brought against a company following a decline in the market price of its securities.

This risk is especially relevant for

us because companies in our industry have experienced significant stock price volatility in recent years.

If we face such litigation,

it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

with any holders of 15% or more of their capital stock until the holder has held the stock for three years unless the Board of Directors

approves the transaction.

These provisions, together with our outstanding preferred stock, could have the effect of delaying, deferring,

or preventing a change of control that stockholders might otherwise consider to be in their best interests.

Our common stock price has been and may

continue to be highly volatile, and stockholders could suffer substantial losses.

The price of our common stock has been, and is

expected to continue to be, volatile.

The stock market in general, and the market for smaller technology and healthcare companies in particular,

has experienced extreme volatility that has often been unrelated to the operating performance of particular companies.

Factors that may

cause volatility in our stock price include, among others, our quarterly financial results, announcements regarding our platform development,

changes in analyst estimates, developments in the AI industry, and broader market conditions.

Stockholders may not be able to sell their

shares at or above the price at which they purchased them.

Risks Relating to General Economic and Market

Adverse economic conditions could reduce

demand for our products and services and harm our business.

Our business is susceptible to market conditions

and risks associated with the digital entertainment and consumer health industries.

Economic conditions that negatively impact discretionary

consumer spending, including inflation, slower growth, unemployment levels, tax rates, interest rates, energy prices, declining consumer

confidence, recession, and other macroeconomic conditions, including those resulting from geopolitical issues and uncertainty, could have

a material adverse impact on our business and results of operations.

Demand for consumer health products such as Keto Air, and for subscription-based

content creation tools such as our RPM platform, may be disproportionately affected by economic downturns that reduce consumer and business

discretionary spending.

Geopolitical developments and trade restrictions,

including those affecting our supply chain for the Keto Air device, could adversely affect our operations.

We source the Keto Air breathalyzer device from

a Hong Kong-based technology group and rely on international shipping and logistics for delivery of inventory to North America.

tensions, trade restrictions, tariffs, export controls, or other regulatory developments affecting U.S.-China or U.S.-Hong Kong trade

could disrupt our supply chain, increase our costs, or prevent us from sourcing sufficient inventory to meet customer demand.

disruption could have a material adverse effect on our consumer health technology segment.

Changes in government spending priorities

and regulatory policy could affect our business in ways we cannot predict.

Our ability to obtain reimbursement or funding

from federal programs may be impacted by possible reductions in federal spending.

federal budget remains subject to significant

uncertainty, and government cost reduction initiatives may impact the ability of relevant agencies such as the FDA to continue to function

at current levels.

Additionally, changes in federal regulatory priorities with respect to artificial intelligence, data privacy, or consumer

protection could result in new or more stringent requirements being imposed on our business, which could require significant compliance

resources and adversely affect our operations.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors